Susquehanna International Group
PTGX icon

Susquehanna International Group’s Protagonist Therapeutics PTGX Stock Holding History

Susquehanna International Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.9M Buy
37,000
+5,100
+16% +$452K ﹤0.01% 4721
2025
Q4 		$2.79M Sell
31,900
-2,600
-8% -$213K ﹤0.01% 5004
2025
Q3 		$2.29M Sell
34,500
-52,900
-61% -$3.01M ﹤0.01% 5489
2025
Q2 		$4.83M Sell
87,400
-36,800
-30% -$1.77M ﹤0.01% 4029
2025
Q1 		$6.01M Buy
124,200
+34,700
+39% +$1.45M ﹤0.01% 3309
2024
Q4 		$3.45M Buy
89,500
+76,900
+610% +$3.35M ﹤0.01% 4194
2024
Q3 		$567K Sell
12,600
-21,500
-63% -$869K ﹤0.01% 8161
2024
Q2 		$1.18M Sell
34,100
-16,100
-32% -$472K ﹤0.01% 6189
2024
Q1 		$1.45M Buy
50,200
+16,600
+49% +$452K ﹤0.01% 6081
2023
Q4 		$770K Buy
33,600
+1,800
+6% +$31.5K ﹤0.01% 7630
2023
Q3 		$530K Sell
31,800
-187,200
-85% -$3.63M ﹤0.01% 8082
2023
Q2 		$6.05M Buy
219,000
+75,300
+52% +$1.88M ﹤0.01% 3222
2023
Q1 		$3.31M Sell
143,700
-15,700
-10% -$264K ﹤0.01% 4136
2022
Q4 		$1.74M Buy
159,400
+57,800
+57% +$488K ﹤0.01% 4978
2022
Q3 		$856K Buy
101,600
+61,200
+151% +$579K ﹤0.01% 7042
2022
Q2 		$320K Sell
40,400
-9,100
-18% -$110K ﹤0.01% 9411
2022
Q1 		$1.17M Sell
49,500
-207,200
-81% -$5.84M ﹤0.01% 6719
2021
Q4 		$8.78M Sell
256,700
-100,800
-28% -$3.19M ﹤0.01% 2911
2021
Q3 		$6.33M Buy
357,500
+318,400
+814% +$13.6M ﹤0.01% 3547
2021
Q2 		$1.75M Sell
39,100
-4,200
-10% -$139K ﹤0.01% 6225
2021
Q1 		$1.12M Sell
43,300
-1,000
-2% -$25.3K ﹤0.01% 7442
2020
Q4 		$893K Buy
+44,300
New +$953K ﹤0.01% 6971

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Susquehanna International Group's PTGX Position: Q1 2026 in Review

Susquehanna International Group increased its Protagonist Therapeutics (PTGX) stake by 1,325% in Q1 2026, buying an estimated $13.8M and bringing the position to 167,576 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Susquehanna International Group first reported a position in PTGX in Q4 2018 and has held it in 25 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Susquehanna International Group held 167,576 shares of Protagonist Therapeutics worth $17.7M as of Q1 2026.
  • Susquehanna International Group bought 155,814 Protagonist Therapeutics shares in Q1 2026, an estimated $13.8M.
  • Protagonist Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2380 holding.
  • Susquehanna International Group first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.